Forward Citations = 24

Loading Chart...

4 inventors (with patents filed for the assignee):

Cheng-Chi Irene Wang (7 out of 10 patents)

Yu-Hsin Tom Lin (6 out of 7 patents)

Konstantin Petrukhin (2 out of 25 patents)

4. Yu-Hsin Tom Lin (1 out of 1 patent)

7 patents: Sort by Forward Citations

1. 12714700 - Methods of treating RBP4 related diseases with triazolopyridines (2026-08-25),

2. 12364693 - Methods of treating metabolic diseases with fused bicyclic pyrazoles (2025-07-22),

3. 12016853 - Methods of treating RBP4 related diseases with triazolopyridines (2024-06-25),

4. 11951100 - Formulations of RBP4 inhibitors and methods of use (2024-04-09),

5. 11389444 - Methods of treating metabolic diseases with fused bicyclic pyrazoles (2022-07-19),

6. 11007186 - Methods of treating RBP4 related diseases with triazolopyridines (2021-05-18),

7. 10245259 - Methods of treating RBP4 related diseases with triazolopyridines (2019-04-02),

Company Overview

Belite Bio, Inc is a biotechnology company focused on developing novel therapies for rare and orphan genetic diseases. Our innovative approach combines cutting-edge research with a deep understanding of patient needs to bring life-changing treatments to those who need them most.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

7 Patents

#3 in Cayman Islands

#119 in Cayman Islands

Cayman Islands, Cayman Islands

Belite Bio, Inc

Forward Citations = 24

4 inventors:

Cheng-Chi Irene Wang (7 out of 10 patents)

Yu-Hsin Tom Lin (6 out of 7 patents)

Konstantin Petrukhin (2 out of 25 patents)

4. Yu-Hsin Tom Lin (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Belite Bio, Inc. Retrieved from https://idiyas.com/company/belite-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]